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Abstract
Introduction Estrogen and androgen signalling pathways exert
opposing influences on the proliferation of mammary epithelial
and hormone-dependent breast cancer cells. We previously
reported that plasma concentrations of 1,1-dichloro-2,2-bis(p-
chlorophenyl)ethylene (p,p'-DDE), the main metabolite of the
insecticide DDT (1,1,1-trichloro-2,2-bis [p-chlorophenyl]ethane)
and a potent androgen antagonist, were associated with tumor
aggressiveness in women diagnosed with breast cancer. We
sought to examine the biological plausibility of this association
by testing the effect of p,p'-DDE on the proliferation of CAMA-1
cells, a human breast cancer cell line that expresses the
estrogen receptor alpha (ERα) and the androgen receptor (AR),
in the presence of physiological concentrations of estrogens
and androgens in the cell culture medium.
Methods The proliferation of CAMA-1 cells was determined in
96-well plates following a 9-day treatment with p,p'-DDE alone
(0.1 to 10 μM) or in combination with 17β-estradiol (E2) (100
pM) and dihydrotestosterone (DHT) (100, 500, or 1,000 pM).
We also assessed p,p'-DDE-induced modifications in cell cycle
entry and the expression of the sex-steroid-dependent genes
ESR1, AR, CCND1, and TFF1 (pS2) (mRNA and/or protein).
Results We found that treatment with p,p'-DDE induced a dose-
response increase in the proliferation of CAMA-1 cells when
cultivated in the presence of physiological concentrations of
estrogens and androgens, but not in the absence of sex steroids
in the cell culture medium. A similar effect of p,p'-DDE was
noted on the proliferation of MCF7-AR1 cells, an estrogen-
responsive cell line that was genetically engineered to
overexpress the AR. DHT added together with E2 to the cell
culture medium decreased the recruitment of CAMA-1 cells in
the S phase and the expression of ESR1  and  CCND1  by
comparison with cells treated with E2 alone. These androgen-
mediated effects were blocked with similar efficacy by p,p'-DDE
and the potent antiandrogen hydroxyflutamide.
Conclusion Our results suggest that p,p'-DDE could increase
breast cancer progression by opposing the androgen signalling
pathway that inhibits growth in hormone-responsive breast
cancer cells. The potential role of environmental antiandrogens
in breast carcinogenesis deserves further investigation.
Introduction
Breast cancer is the most common cancer in women, with
more than 1,000,000 new cases occurring in the year 2000
worldwide [1]. Risk factors for the disease include high plasma
estrogen levels [2], high levels of expression of estrogen
receptors (ERs) in mammary tissue [3,4], and high breast den-
sity as revealed by mammography screening [5]. The adminis-
tration of antiestrogens constitutes the most useful treatment
for hormone-dependent breast cancer [6] and was shown to
be effective in preventing breast cancer in clinical trials [7].
In view of the pivotal role of estrogens in the pathogenesis of
breast cancer, exposure to xenobiotics that possess
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estrogenic properties, referred to as xenoestrogens, has been
suggested to explain the increase in the incidence of breast
cancer noted over the last four decades in industrialized coun-
tries. In vitro studies revealed that the loss of normal cell cycle
control in hormone-dependent breast cancer cells can result
from treatment with xenoestrogens as indicated by increased
cell proliferation and modulation of estrogen-sensitive molecu-
lar parameters [8,9]. However, the sum of evidence from sev-
eral epidemiological studies that investigated the relationship
between breast cancer and exposure to persistent organo-
chlorines, some of them with known estrogenic properties,
does not support a link between any of these compounds and
breast cancer risk [10,11].
Environmental compounds that bind the androgen receptor
(AR) constitute another class of endocrine disruptors that
have received growing interest over the last decade [12,13].
Androgens control the proliferation of mammary epithelial cells
in nonhuman primates [14,15] as well as that of several breast
cancer cell lines [16,17]. Androgens were shown to be effec-
tive in complementing the treatment of hormone-dependent
breast cancer [18]. Furthermore, androgenic compounds can
induce a remission after failure of antiestrogenic therapy
(reviewed in [19]). One, therefore, may anticipate that expo-
sure to antiandrogens could increase breast cancer risk or
favor its progression.
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE), the
main DDT (1,1,1-trichloro-2,2-bis [p-chlorophenyl]ethane)
metabolite, is a highly persistent molecule that accumulates in
body fat with age [20] and is a potent androgen antagonist
[12]. In the course of a case-control study on organochlorine
and breast cancer, we previously reported that, among cases,
plasma  p,p'-DDE concentrations were associated with the
aggressiveness of breast cancer [21]. We speculated that this
relationship could be explained by the antiandrogenic action of
the compound on breast cancer cells that would favor their
proliferation and in turn breast cancer progression. To test this
hypothesis, we used CAMA-1 breast cancer cells cultivated in
the presence of physiologically relevant concentrations of sex
hormones as an in vitro model of breast cancer progression.
Both ER alpha (ERα) and AR are expressed in CAMA-1 cells;
estrogens stimulate their proliferation, whereas androgens
oppose the estrogen-induced proliferative effect [22]. Here,
we show that p,p'-DDE can markedly increase the proliferation
of CAMA-1 cells in conditions in which estrogens and andro-
gens are competing for the control of cell cycle gene
expression.
Materials and methods
Reagents
17β-estradiol (E2) was purchased from Sigma-Aldrich (St.
Louis, MO, USA) and dihydrotestosterone (DHT) from Ster-
aloids, Inc. (Newport, RI, USA), whereas hydroxyflutamide
(OHF) was kindly donated by Schering-Plough Corporation
(Kenilworth, NJ, USA). These compounds were dissolved in
ethanol. p,p'-DDE was purchased from Cerilliant Corporation
(Round Rock, TX, USA) and was dissolved in dimethylsulfox-
ide. Final concentrations of vehicles in the cell culture medium
were 0.1% (vol/vol). Aprotinin, leupeptin, phenylmethylsulfonyl
fluoride, and sodium orthovanadate were purchased from
Sigma-Aldrich.
Cell proliferation assays
CAMA-1 and MCF-7 cells were purchased from the American
Type Culture Collection (Manassas, VA, USA). MCF7-AR1
cells were kindly provided by Ana M Soto (Tufts University,
Medford, MA, USA). CAMA-1 cells were maintained in phenol
red-free Roswell Park Memorial Institute (RPMI) medium sup-
plemented with 10% (vol/vol) fetal bovine serum (FBS) from
Wisent Inc. (St.-Bruno, QC, Canada), 1.0 mM pyruvate, 2.0
mM L-glutamine, 0.1 μg/mL streptomycin, and 0.1 U/mL pen-
icillin in a humidified atmosphere of 5% CO2 at 37°C. Two
thousand cells per well were seeded in 200 μL phenol red-free
RPMI-10% FBS in 96-well plates (6 wells per treatment) and
were incubated during 24 hours at 37°C. The complete
medium was then substituted for FBS-free medium for a 24-
hour period. On day 1 of the experiment, the FBS-free medium
was replaced by a medium containing 10% dextran-coated
charcoal-treated FBS (DCC-FBS) from Wisent Inc., the hor-
mones, and test chemicals (or vehicles). Cells were grown
over a 9-day period with a medium replacement every 3 days.
The medium was then removed and nucleic acids were
stained using the CyQuant® kit purchased from Molecular
Probes Inc. (now part of Invitrogen Corporation, Carlsbad, CA,
USA) as described by the manufacturer. Cell proliferation for
the control treatment was arbitrarily set at 1, and results were
expressed as fold induction over the control.
MCF-7 and MCF7-AR1 cells were maintained in phenol red-
free Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% (vol/vol) FBS, 1.0 mM pyruvate, 2.0 mM L-
glutamine, 0.1 μg/mL streptomycin, 0.1 U/mL penicillin, and 1
μg/mL insulin in a humidified atmosphere of 5% CO2 at 37°C.
One thousand cells per well were seeded in 200 μL of phenol
red-free DMEM-10% FBS in 96-well plates (6 wells per treat-
ment) and were incubated during 24 hours at 37°C. The com-
plete medium was removed and cells were washed with
phosphate-buffered saline (PBS). Then a medium containing
10% DCC-FBS, the hormones, and test chemicals (or vehi-
cles) were added. Cells were grown over a 6-day period with-
out medium replacement, and proliferation was assessed as
described above for CAMA-1 cells.
Cell cycle analysis
Fifty thousand cells per well were seeded in 1 mL phenol red-
free RPMI-10% FBS in 24-well plates and incubated during
24 hours at 37°C. The medium was replaced by FBS-free
medium during 48 hours to promote G0/G1 synchronization
[23]. FBS-free medium was then replaced by a mediumAvailable online http://breast-cancer-research.com/content/10/1/R16
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containing 10% DCC-FBS, hormones, and test chemicals (or
vehicles) for a 24-hour incubation period at 37°C. Cells were
harvested following trypsinization, fixed in 70% ethanol for 30
minutes at -30°C, and stained with propidium iodide (50 μg/
mL) in PBS containing 40 U/mL RNase A for 1 hour at 37°C.
The DNA content in each cell was determined by flow cytom-
etry analysis using the Wallac 1420 Multilabel Counter from
PerkinElmer Life and Analytical Sciences, Inc. (Waltham, MA,
USA).
Gene expression levels
Two million cells were seeded into 10-cm dishes in 10 mL of
phenol red-free RPMI-10% FBS and were incubated during
24 hours at 37°C. The complete medium was then substituted
for FBS-free medium for a 24-hour period. The FBS-free
medium was subsequently replaced by a medium containing
10% DCC-FBS, the hormones, and test chemicals (or vehi-
cles), and cells were grown over a 24-hour period. Duplicate
cell cultures were used for each treatment: one dish was used
for RNA and the other for total cell extracts. RNA was isolated
with TRIzol® from Gibco (now part of Invitrogen Corporation)
as described by the manufacturer and diluted in 40 μL of die-
thyl pyrocarbonate-treated H2O. mRNAs were reverse-tran-
scribed by Super Script II™ using Oligo(dt) primer from
Invitrogen Corporation as described by the manufacturer in a
final volume of 50 μL. An amount of 500 ng of total RNA was
included as template for each reaction. The amount of cDNA
used for polymerase chain reaction (PCR) was adjusted for
each target gene. To assess ESR1 mRNA (forward primer: 5'-
AATTCAGATAATCGACGCCAG-3'; reverse: 5'-GTGTT-
TCAACATTCTCCCTC-CTC-3'; annealing temperature (Tm)
= 58°C; 344 base pairs [bp]) [24], a 10-μL aliquot of cDNA
was used compared with 1 μL for β-actin (forward primer: 5'-
CGTGACATTAAGGAGAAGCTGTGC-3'; reverse: 5'-
CTCAGGAGGAGCAATGATCTTGAT-3'; Tm = 58°C; 375
bp) [25], while 10 and 5 μL of amplified product were loaded
on an 8% polyacrylamide gel for ESR1 and β-actin, respec-
tively. To evaluate mRNAs for CCND1 (forward primer: 5'-
CGGAGGAGAACAAACAGATC-3'; reverse: 5'-GGGTGT-
GCAAGCCAGGTCCA-3'; Tm = 55°C; 350 bp) [26] and AR
(forward primer: 5'-GTCAAAAGCGAAATGGGCCCC-3';
reverse: 5'-CTTCTGGGTTGTCTCCTCAGT-3'; Tm = 60°C;
420 bp) [27], we used 5-μL aliquots of cDNA for both genes
and a 2-μL aliquot for β-actin while 10 μL of amplified prod-
ucts was loaded on the gel. To evaluate mRNAs for TFF1 (for-
ward primer: 5'-TTTGGAGCAGAGAGGAGGCAATGG-3';
reverse: 5'-TGGTATTAGGATAGAAGCACCAGGG-3'; Tm =
58°C; 240 bp) [28], we used 2-μL aliquots of cDNA and a 2-
μL aliquot for β-actin while 10 μL of amplified products was
loaded on the gel. Taq DNA polymerase and deoxynucleotides
(Roche Diagnostics, Basel, Switzerland) were used as
described by the manufacturer in a 50-μL final volume. The
PCR settings were adjusted to complete each reaction within
the linear portion of amplification. PCR conditions were one 5-
minute cycle at 95°C, 25 (β-actin) or 30 cycles (target
mRNAs) each comprising a 30-second step at 95°C, followed
by a 30-second step at primer-specific Tm and a 45-second
step at 72°C, and one last cycle of 7 minutes at 72°C. Nega-
tive controls were included for each reaction. PCR products
were stained with ethidium bromide and captured with a 16-
bit camera. Densitometry was determined by Quantity One 1-
D Software Analysis from Bio-Rad Laboratories, Inc. (Her-
cules, CA, USA) and normalized with β-actin.
Immunoblotting
Floating cells were recovered with the medium and pooled
with the adherent cells that were harvested by scraping in 2
mL of ice-cold PBS, centrifuged, and resuspended in 600 μL
of lysis buffer containing 50 mM Hepes, pH 7.5; 1 mM EGTA
(ethylene glycol tetraacetic acid), pH 8; 150 mM NaCl; 1.5
mM MgCl2; 10 mM sodium pyrophosphate; 200 μM sodium
orthovanadate; 100 mM NaF; 1% Triton X-100; 10% glycerol;
and a protease inhibitor cocktail from EMD Biosciences, Inc.
(San Diego, CA, USA). Insoluble material was removed by
centrifugation (10 minutes at 13,000 g). Thirty micrograms of
the cellular extract was resolved on PROTEAN® II (Bio-Rad
Laboratories, Inc.) 10% SDS-polyacrylamide gels. The pro-
teins were electroblotted onto 0.45-μM polyvinyl difluoride
membranes purchased from Millipore Corporation (Billerica,
MA, USA). Membranes were blocked at room temperature for
1 hour in PBS containing 5% (wt/vol) dried milk and incubated
2 hours at 37°C with the specific antibody diluted in PBS con-
taining 1% (wt/vol) dried milk. Antibodies against ERα, AR,
and cyclin D1 were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA), and anti-actin was from
Cedarlane Laboratories Limited (Burlington, ON, Canada).
Membranes were washed in PBS containing 0.1% (vol/vol)
Tween 20 followed by a 1-hour incubation with specific immu-
noglobulin G horseradish peroxidase-conjugated antibodies
from Jackson ImmunoResearch Laboratories, Inc. (West
Grove, PA, USA) and then incubated in Immun Star HRP Sub-
strate (Bio-Rad Laboratories, Inc.) as described by the manu-
facturer. Signals were analyzed as described above for
reverse transcription-polymerase chain reaction and were nor-
malized for actin within the same membrane according to the
method of Liao and colleagues [29].
Statistical analyses
Concentration-response relationships were tested using linear
regression analysis. Group means were compared using an
analysis of variance (ANOVA) with specific contrasts or an
ANOVA followed by the Bonferroni post hoc test. One-tail
tests were performed for cell proliferation experiments
because of a priori hypotheses regarding treatment effects
(that is, inhibition for androgens and induction for antiandro-
gens). All other tests were two-sided. All statistical analyses
were performed using the SPSS for Windows software (ver-
sion 11.5.0; SPSS Inc., Chicago, IL, USA).Breast Cancer Research    Vol 10 No 1    Aubé et al.
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Results
Level of expression of ERα and AR in cell lines
Figure 1 displays the relative levels of ERα and AR in CAMA-
1, MCF7-AR1, and wild-type MCF-7 cells. CAMA-1 and
MCF7-AR1 cells expressed, respectively, 6.5-fold (P < 0.01)
and 7.5-fold (P < 0.01) more AR proteins compared with wild-
type MCF-7 cells, whereas ERα expression levels were not dif-
ferent among the cell lines. Because of their high levels of
expression of ERα and AR, CAMA-1 and MCF7-AR1 cells
were used to investigate the capacity of p,p'-DDE to disrupt
the estrogen-androgen balance and increase cell proliferation.
Cell proliferation
Before testing the effect of the environmental antiandrogen
p,p'-DDE on cell growth, we first assessed the proliferative
response of CAMA-1 cells in the presence of estrogens and
androgens in the cell culture medium over a 9-day period. Fig-
ure 2a shows the concentration-response relationship for E2-
induced proliferation of CAMA-1 cells. We used a 100-pM
concentration of E2, which generates near maximal prolifera-
tion, in combination with increasing concentrations of DHT
and observed an inverse dose-response relationship between
androgen concentrations (log-transformed) and cell prolifera-
tion (regression coefficient [β] = -0.887; P < 0.001) (Figure
2b). Combined treatment with 100, 500, or 1,000 pM DHT
reduced the E2-induced proliferative response by 27% (P <
0.05), 54% (P < 0.001), and 60% (P < 0.001), respectively.
To investigate the potential of p,p'-DDE to increase the prolif-
eration of CAMA-1 cells cultivated in the presence of endog-
enous estrogens and androgens, increasing concentrations of
p,p'-DDE were added to the cell culture medium together with
E2  and DHT. p,p'-DDE induced concentration-related
increases in CAMA-1 cell proliferation in the presence of 100
pM E2 and DHT added at a concentration of 100 pM (β =
0.674, P < 0.001; Figure 3a), 500 pM (β = 0.629, P < 0.001;
Figure 3b), or 1,000 pM (β = 0.663, P < 0.001; Figure 3c).
Concentrations of p,p'-DDE as low as 2 μM caused a statisti-
cally significant increase in cell proliferation compared with the
E2+DHT treatment (P < 0.01; Figure 3a,b); the 5-μM concen-
tration completely abolished the inhibitory effect of DHT on
cell proliferation. In the absence of sex steroid hormones, p,p'-
DDE added to the cell culture medium induced only a slight
proliferative response (1.3-fold induction at 10 μM, P < 0.01;
Figure 3d).
The capacity of p,p'-DDE to increase breast cancer cell prolif-
eration in the presence of sex steroids was also tested in
MCF7-AR1 cells. Szelei and colleagues [30], who genetically
engineered these cells that overexpress the AR, previously
reported that DHT added together to E2 decreased the prolif-
eration of MCF7-AR1 cells compared with treatment with E2
alone. We observed that p,p'-DDE induced a concentration-
related increase in MCF7-AR1 proliferation in the presence of
10 pM E2 and 100 pM DHT (β = 0.513, P = 0.01; Figure 4a).
A 2-μM concentration of p,p'-DDE caused a 2-fold increase in
cell proliferation compared with the E2+DHT treatment (P <
0.05). In the absence of sex steroid hormones, p,p'-DDE
added to the cell culture medium also induced a significant
proliferative response (2.9- and 3.6-fold induction at 5 and 10
μM, respectively, P < 0.001; Figure 4b).
Figure 1
Expression of the estrogen receptor alpha (ERα) and the androgen  receptor (AR) in CAMA-1, MCF-7, and MCF7-AR1 breast cancer cell  lines at the protein level Expression of the estrogen receptor alpha (ERα) and the androgen 
receptor (AR) in CAMA-1, MCF-7, and MCF7-AR1 breast cancer cell 
lines at the protein level. Cell extracts were prepared during exponential 
proliferation in maintenance medium containing 10% fetal bovine 
serum. Immunoblots were performed as described in Materials and 
methods. (a) A representative immunoblot. (b) Relative expression of 
sex steroid receptors quantified to actin content. Each bar represents 
the mean ± standard error of the mean of four independent experi-
ments. Double asterisk indicates P < 0.01 versus wild-type MCF-7 
cells as determined by an analysis of variance followed by a Bonferroni 
post hoc test.Available online http://breast-cancer-research.com/content/10/1/R16
Page 5 of 12
(page number not for citation purposes)
Recruitment of CAMA-1 cells in S phase
To better characterize the proliferative response induced by
p,p'-DDE on CAMA-1 cells, we measured cell transition from
the G0/G1 to the S phase after a 24-hour treatment with p,p'-
DDE in the presence of sex steroid hormones and compared
the results to those obtained with the potent antiandrogen
OHF. Adding 1 nM DHT in combination with 1 nM E2 reduced
by more than 50% (P < 0.05) the percentage of cells in the S
phase observed in the presence of 1 nM E2 alone (Figure 5a).
Figure 2
Effects of 17β-estradiol (E2) and dihydrotestosterone (DHT) on the pro- liferation of CAMA-1 cells Effects of 17β-estradiol (E2) and dihydrotestosterone (DHT) on the pro-
liferation of CAMA-1 cells. E2 induces cell proliferation in a concentra-
tion-dependent manner (a) while increasing concentrations of DHT 
inhibit the proliferative response triggered by 100 pM E2 (b). Cell prolif-
eration was assessed after 9 days of treatment. Each bar represents 
the mean ± standard error of the mean of three (a) and four (b) inde-
pendent experiments. Single asterisk indicates P < 0.05, double aster-
isk P < 0.01, and triple asterisk P < 0.001 versus E2 treatment by an 
analysis of variance followed by a one-tail Bonferroni post hoc test.
Figure 3
p,p'-DDE increases the proliferation of CAMA-1 cells in the presence of  17β-estradiol (E2) and dihydrotestosterone (DHT) p,p'-DDE increases the proliferation of CAMA-1 cells in the presence of 
17β-estradiol (E2) and dihydrotestosterone (DHT). E2 was added at a 
concentration of 100 pM, and DHT was added at concentrations of 
100 pM (a), 500 pM (b), or 1,000 pM (c). p,p'-DDE alone has little 
impact on CAMA-1 proliferation (d). Cell proliferation was assessed 
after 9 days of treatment. Each bar represents the mean ± standard 
error of the mean of four independent experiments. Double asterisk 
indicates P < 0.01 versus E2+DHT treatment and †† indicates P < 
0.01 versus 0.1 μM p,p'-DDE as determined by an analysis of variance 
followed by a one-tail Bonferroni post hoc test. p,p'-DDE, 1,1-dichloro-
2,2-bis(p-chlorophenyl)ethylene.Breast Cancer Research    Vol 10 No 1    Aubé et al.
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The addition of either 10 μM p,p'-DDE or 1 μM OHF to the cell
culture medium completely abolished the androgen-mediated
decrease in the percentage of CAMA-1 cells entering the cell
cycle (P  < 0.05 versus E2+DHT treatment). Treatment-
induced changes in the percentage of cells in G0/G1 were of
similar magnitude to those observed for the S phase but in the
opposite direction (Figure 5b). The proportion of cells in the
G2/M phase was slightly increased by the 1-nM E2 treatment
(P < 0.05), but adding DHT and antiandrogens in combination
with E2 did not modify the E2-induced response (Figure 5c).
Modification of sex-steroid-dependent gene expression 
by p,p'-DDE
To further elucidate the mechanism underlying the induction of
CAMA-1 cell proliferation by p,p'-DDE, we studied the effect
of a 24-hour treatment with p,p'-DDE on the expression of sex-
hormone-sensitive genes at the mRNA level, in the presence
of E2 and DHT, and compared the results with those obtained
by treating the cells with OHF in combination with the endog-
enous hormones. The mean cyclin D1 mRNA level was
increased by 50% (P < 0.01) in E2-treated cells compared
with that of the control cells (Figure 6a), whereas 1 nM DHT
significantly reduced this estrogenic effect (P < 0.01 versus
Figure 4
p,p'-DDE increases the proliferation of MCF7-AR1 cells in the pres- ence of 17β-estradiol (E2) and dihydrotestosterone (DHT) (a) or when  added alone to the cell culture medium (b) p,p'-DDE increases the proliferation of MCF7-AR1 cells in the pres-
ence of 17β-estradiol (E2) and dihydrotestosterone (DHT) (a) or when 
added alone to the cell culture medium (b). Cell proliferation was 
assessed after 6 days of treatment. Each bar represents the mean ± 
standard error of the mean of four independent experiments. A single 
asterisk indicates P < 0.05 versus E2+DHT treatment and ††† indicates 
P < 0.001 versus 0.1 μM p,p'-DDE as determined by an analysis of var-
iance followed by a one-tail Bonferroni post hoc test. p,p'-DDE, 1,1-
dichloro-2,2-bis(p-chlorophenyl)ethylene.
Figure 5
p,p'-DDE increases G0/G1-S transition of CAMA-1 cells in the pres- ence of 17β-estradiol (E2) and dihydrotestosterone (DHT) p,p'-DDE increases G0/G1-S transition of CAMA-1 cells in the pres-
ence of 17β-estradiol (E2) and dihydrotestosterone (DHT). Treatment-
related changes are shown for the percentage of cells in S (a), G0/G1 
(b), and G2/M (c) phases. Synchronization of the cells – 90% of cells 
in G0/G1 and less than 3% in S phase – was induced by a 48-hour 
serum deprivation period. Cells were subsequently treated during 24 
hours with hormones and antiandrogens (or their vehicles). Each bar 
represents the mean ± standard error of the mean of four independent 
experiments in duplicate. Single asterisk indicates P < 0.05, double 
asterisk P < 0.01, and triple asterisk P < 0.001 versus control, † indi-
cates P < 0.05 versus E2 treatment, and ‡ indicates P < 0.05 versus 
E2+DHT treatment as determined by an analysis of variance with spe-
cific contrasts. OHF, hydroxyflutamide; p,p'-DDE, 1,1-dichloro-2,2-
bis(p-chlorophenyl)ethylene.Available online http://breast-cancer-research.com/content/10/1/R16
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E2 alone). Treatment with either 10 μM p,p'-DDE or 1 μM OHF
partly abolished the inhibition of cyclin D1 mRNA expression
induced by DHT, resulting in mean expression levels that are
not significantly different from that induced by E2  alone.
Although E2 alone did not modulate ERα mRNA expression,
the E2+DHT treatment appeared to decrease the mean
expression level compared with that induced by E2 alone (Fig-
ure 6b), whereas p,p'-DDE or OHF partly offset this downreg-
ulation. However, differences between treatments did not
reach statistical significance. AR mRNA mean expression level
was decreased by 27% following DHT treatment compared
with E2 treatment (P < 0.01; Figure 6c), whereas treatment
with either 10 μM p,p'-DDE or 1 μM OHF completely antago-
nized this inhibition (P < 0.01 versus E2+DHT). pS2 mRNA
mean expression level was increased by 50% (P < 0.01) fol-
lowing E2 treatment compared with the control (Figure 6d).
The E2+DHT treatment induced a slightly lower expression of
pS2 mRNA compared with that caused by E2 alone, but the
difference was not statistically significant. p,p'-DDE added
together with E2 and DHT induced a greater pS2 mRNA
expression than did the E2+DHT treatment (P < 0.05).
We also evaluated the modulation of cyclin D1, ERα, and AR
protein expression levels by p,p'-DDE treatment in CAMA-1
cells in the presence of endogenous sex steroids. Cyclin D1
level was increased by 80% (P < 0.01) in cells treated with 1
nM E2 compared with the vehicle-treated cells (Figure 7a),
whereas adding 1 nM DHT in combination with E2 blocked this
increase (P < 0.01 versus E2 alone). The addition of either 10
μM p,p'-DDE or 1 μM OHF to the cell culture medium together
with E2 and DHT completely abolished this DHT-mediated
inhibition of cyclin D1 expression (P < 0.01 versus E2+DHT).
Whereas E2 alone was without effect, the combined E2+DHT
treatment markedly decreased ERα protein level (more than
50%) as compared with that observed following E2 treatment
or control (P < 0.05; Figure 7b). p,p'-DDE or OHF treatment
again abolished this androgen-mediated inhibition (P < 0.01
versus E2+DHT). A different response pattern was observed
for AR protein expression (Figure 7c). E2 treatment decreased
by 28% (P < 0.05) the mean AR protein expression level com-
pared with control, whereas AR protein level was significantly
increased following the combined E2+DHT treatment com-
pared with the value noted following E2 treatment alone (P <
0.01). The androgen-mediated increase in AR protein level
was antagonized by adding OHF in the incubation medium (P
< 0.05 versus E2+DHT) but not p,p'-DDE (Figure 7c).
Discussion
We tested the capacity of p,p'-DDE to stimulate the prolifera-
tion of CAMA-1 cells, a human breast adenocarcinoma cell
line that expresses both the ERα and the AR. We showed that
p,p'-DDE strongly induces the proliferation of CAMA-1 cells in
a concentration-dependent manner but only when cells are
grown in the presence of physiological concentrations of
endogenous sex steroid hormones. When concentrations of
Figure 6
p,p'-DDE modulates the expression of sex-steroid-dependent genes in  CAMA-1 cells at the mRNA level p,p'-DDE modulates the expression of sex-steroid-dependent genes in 
CAMA-1 cells at the mRNA level. mRNA levels were determined by a 
semiquantitative polymerase chain reaction after a 24-hour treatment 
with hormones and antiandrogens (or vehicles) as described in Materi-
als and methods. mRNAs for CCND1 (a), ESR1 (b), AR (c), and TFF1 
(d) were quantified relative to β-actin mRNA. A representative gel elec-
trophoresis is shown below each panel. Each bar represents the mean 
± standard error of the mean of six independent experiments. Double 
asterisk indicates P < 0.01 versus control, †† indicates P < 0.01 versus 
E2 treatment, and ‡ and ‡‡ indicate, respectively, P < 0.05 and P < 
0.01 versus E2+DHT treatment as determined by an analysis of vari-
ance with specific contrasts. AR, androgen receptor; DHT, dihydrotes-
tosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha; OHF, 
hydroxyflutamide; p,p'-DDE, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethyl-
ene.Breast Cancer Research    Vol 10 No 1    Aubé et al.
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E2 and DHT are such that the androgen signalling pathway
partly counteracts the influence of the estrogen signalling
pathway on cell proliferation, p,p'-DDE blocks the AR, result-
ing in CCND1 overexpression, the recruitment of cells in the
S phase, and in turn increased cell proliferation.
The capacity of the androgen DHT to inhibit the proliferation of
CAMA-1 breast cancer cells was previously reported by
Lapointe and Labrie [22]. Similarly to our results, these authors
reported a dose-dependent inhibition of cell proliferation and
maximal inhibition of E2-stimulated proliferation at the 1-nM
DHT concentration. Other groups have reported that andro-
gens can inhibit the proliferation of several hormone-depend-
ent breast cancer cell lines, including MCF-7, T47D, and ZR-
75-1 cells [16,17]. We tested these and other wild-type
breast cancer cell lines, but in our hands only CAMA-1 cells
responded strongly and reproducibly to androgens. We there-
fore elected to use CAMA-1 cells grown in the presence of
estrogens and androgens as an in vitro model for investigating
the role of environmental antiandrogens in breast cancer
progression.
p,p'-DDE also induced the proliferation of MCF7-AR1 cells in
the presence of E2 and DHT in the cell culture medium. These
stably transfected cells that overexpress the AR are derived
from MCF-7 cells [30], an estrogen-sensitive breast cancer
cell line that has been widely used in proliferation assays for
testing the estrogenic potential of chemicals (E-Screen bio-
assay). In contrast to results with CAMA-1 cells, p,p'-DDE also
increased the proliferation of MCF7-AR1 cells in the absence
of sex hormones (Figure 4b). This direct proliferative effect,
which is likely due to the estrogenic potential of p,p'-DDE, was
similar to that obtained by other groups with native MCF-7
cells [31-33]. Therefore, activation of the estrogenic pathway
could be responsible in part for the induction of proliferation
observed when MCF7-AR1 cells were cotreated with p,p'-
DDE, E2, and DHT (Figure 4a). Interestingly, in the presence of
E2 and DHT, the proliferation of MCF7-AR1 cells was induced
by lower concentrations of p,p'-DDE than those required in the
absence of sex steroids. This could be explained by the
greater affinity of p,p'-DDE for AR than for ERα [12], resulting
in the predominance of the AR signalling pathway at low con-
centrations. p,p'-DDE and several other compounds possess
both antiandrogenic and estrogenic activities [34] and there-
fore may increase breast cancer cell proliferation through
interference with both estrogenic and androgenic pathways.
Our data suggest that one of the key events in the mechanism
of action through which p,p'-DDE increases CAMA-1 cell pro-
liferation is the upregulation of CCND1 expression. Indeed,
we observed concomitant increases in CCND1 expression
and S phase entry following treatment with p,p'-DDE in the
presence of sex steroids compared with responses induced
by the E2+DHT treatment. This mechanism is apparently com-
mon to antiandrogens in general as similar results were
Figure 7
p,p'-DDE modulates the expression of sex-steroid-dependent genes in  CAMA-1 cells at the protein level p,p'-DDE modulates the expression of sex-steroid-dependent genes in 
CAMA-1 cells at the protein level. Immunoblots were performed after 
24 hours of treatment with hormones and antiandrogens (or vehicles) 
as described in Materials and methods. Cyclin D1 (a), ERα (b), and AR 
(c) protein levels were quantified relative to actin content. Each bar rep-
resents the mean ± standard error of the mean of six independent 
experiments. A representative immunoblot is shown below each panel. 
Single asterisk indicates P < 0.05 and double asterisk P < 0.01 versus 
control; † and †† indicate, respectively, P < 0.05 and P < 0.01 versus 
E2 treatment; and ‡ and ‡‡ indicate, respectively, P < 0.05 and P < 
0.01 versus E2+DHT treatment as determined by an analysis of vari-
ance with specific contrasts. AR, androgen receptor; DHT, dihydrotes-
tosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha; OHF, 
hydroxyflutamide; p,p'-DDE, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethyl-
ene.Available online http://breast-cancer-research.com/content/10/1/R16
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observed with OHF. Cyclin D1 is a major regulator of the G1/
S phase transition and a rate-limiting step in estrogen-induced
mammary cell proliferation [35,36]. This oncogene has been
shown to transform breast cells in transgenic mice [37] and is
frequently overexpressed in primary breast cancer, especially
in invasive carcinomas [38,39]. In our experiments, the cyclin
D1 protein expression pattern was remarkably similar to its
corresponding mRNA expression pattern, suggesting that
cyclin D1 expression is mostly controlled at the mRNA level in
CAMA-1 cells.
Our results also suggest that ESR1 expression is involved in
the mechanism through which antiandrogens increase the
expression of CCND1  in CAMA-1 cells. Effectively, we
observed similar treatment-related effects for the expression of
CCND1 and ESR1: DHT decreased the expression of both
genes whereas treatment with either p,p'-DDE or OHF
increased their expression in the presence of E2 and DHT.
ERα has been shown to be an important transcription factor
that acts indirectly on the CCND1 promoter [40-42]. That
androgens can downregulate the expression of ERα was pre-
viously reported in the ZR-75-1 breast cancer cell line and in
MCF7-AR1 cells [30,43].
We did not observe a reduction in ERα protein expression fol-
lowing treatment of CAMA-1 cells with E2. This result is in con-
trast to those reported in the literature showing that estrogens
induce a downregulation of the ERα protein in hormone-
dependent breast cancer cell lines as well as in transfected
ER-negative cell lines [44-49]. The estrogen-induced down-
regulation of ERα occurs mainly through the regulated degra-
dation of the receptor protein by the 26S proteasome [49,50].
Hence, CAMA-1 cells appear different than other breast can-
cer cell lines in that regard.
We found that the AR protein is downregulated by estradiol
without any effect on the corresponding mRNA level. There-
fore, this downregulation may occur either at the level of trans-
lation or through a decrease in AR stability. In contrast, DHT
caused a significant increase in AR protein level in CAMA-1
cells. Similarly to our results, Andò and colleagues [51]
observed that the activation of AR by DHT resulted in the inhi-
bition of MCF-7 cell proliferation; this effect was accompanied
by an increase in AR protein cell content.
Our results are compatible with the existence of a crosstalk
between androgen and estrogen signalling pathways which
controls breast cancer cell proliferation, similarly to that
described by Lanzino and colleagues [52] in MCF-7 cells.
These authors showed that AR activation influences ERα sig-
nalling by reducing ERα cellular content and by competition to
recruit the coregulator ARA70, which although first described
as a specific AR coregulator [53] also increases the transcrip-
tional activity of ERα [52]. We speculate that binding of p,p'-
DDE to the AR would increase the amount of ARA70 available
to interact with ERα, thereby increasing the estrogenic signal-
ling pathway and in turn cell proliferation. Additional experi-
ments are needed to substantiate this mechanism of action in
CAMA-1 cells.
Some evidence in the literature indicates that exposure to
antiandrogens could increase breast cancer risk through per-
turbation of the androgen-estrogen crosstalk in mammary epi-
thelial cells. Indeed, Dimitrakakis and colleagues [15] have
reported an increase in mammary epithelial cell proliferation
following treatment of female rhesus monkeys with flutamide
(the precursor of OHF). Furthermore, a downregulation of ERα
expression and a decrease in mammary epithelial cell prolifer-
ation were observed following treatment of ovariectomized
rhesus monkeys with a combined estradiol/testosterone treat-
ment compared with the group treated with estradiol alone
[15]. ERα is weakly expressed in normal mammary epithelial
cells and only a few cells express this gene [54], including the
putative breast stem cells [55]. A rigorous control must be
exerted on ERα expression in order to limit the number of 'at
risk' and precancerous cells in the breast [54], which may be
compromised by environmental antiandrogens.
Our results add biological plausibility to the association noted
in our previous epidemiological study between plasma levels
of p,p'-DDE and the aggressiveness of breast cancer. We
observed that women with breast cancer who had higher
plasma concentrations of this compound were at greater risk
of having a larger tumor and axillary lymph node invasion than
women with lower concentrations [21]. Although the informa-
tion is extremely limited, the association between organochlo-
rines and disease severity and progression is interesting and
worthy of further investigation [11]. By blocking the andro-
genic pathway, p,p'-DDE may favor the proliferation of normal
and breast cancer cells and accelerate breast cancer
progression. Our results appear particularly relevant for cases
with tumors expressing high levels of ERα and AR. In that con-
text, it is worth mentioning that 70% to 90% of primary breast
tumors express the AR (reviewed in [56]).
We also noted that p,p'-DDE increased the expression of pS2
in CAMA-1 cells (Figure 6d), an estrogen-dependent protein
that increases the migration of hormone-dependent breast
cancer cells [57]. The failure of OHF to increase pS2 expres-
sion over the level induced by the E2+DHT treatment suggests
that this effect may be due to the estrogenic activity of p,p'-
DDE. Normal breast cells secrete low levels of this chemoat-
tractant trefoil protein [58]. This effect of p,p'-DDE could con-
tribute to breast cancer aggressiveness. Additional
experiments with animal models are required to further support
this hypothesis.
To our knowledge, this is the first report showing that p,p'-DDE
can significantly stimulate the proliferation of a breast cancer
cell line in the presence of androgens and estrogens. OurBreast Cancer Research    Vol 10 No 1    Aubé et al.
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model is unique in that compounds are tested for their capac-
ity to stimulate cell proliferation in the presence of physiologi-
cally relevant concentrations of sex steroids. Although tests
based on the proliferation of hormone-dependent breast can-
cer cells have been used extensively in the past, none of them
can detect compounds that perturb the crosstalk between
estrogenic and androgenic pathways [59]. This experimental
model could be used to screen for compounds that can
increase breast cancer progression because of their estro-
genic potential, their antiandrogenic capacity, or a combina-
tion of both since many environmental estrogens are also AR
antagonists [34].
Conclusion
Our study provides new evidence that environmental antian-
drogens might favor breast cancer progression. Figure 8 illus-
trates part of the mechanism through which p,p'-DDE may
induce the proliferation of hormone-dependent cells in the
breast. Additional investigations are under way to investigate
the effect on breast cancer cell proliferation of a complex mix-
ture of environmental chemicals which comprises compounds
with estrogenic and antiandrogenic activities.
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Figure 8
A proposed mechanism for p,p'-DDE-induced proliferation of hormone-dependent cells A proposed mechanism for p,p'-DDE-induced proliferation of hormone-dependent cells. Lipophilic p,p'-DDE is stored in adipocytes and can diffuse 
to reach hormone-dependent cells. p,p'-DDE confers a proliferative advantage to precancerous hormone-dependent cells by blocking the androgen 
receptor (AR) signalling pathway that represses cell growth. Tumor development is favored through the upregulation of the oncogene CCND1, a key 
molecular event in the deregulation by p,p'-DDE of the crosstalk between estrogen receptor alpha (ERα) and the AR. E2, 17 β-estradiol; DHT, dihy-
drotestosterone; p,p'-DDE, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene.Available online http://breast-cancer-research.com/content/10/1/R16
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